newsfilter
← Latest News
GlobeNewswire·

Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025

RVPH
  • Reviva Pharmaceuticals announced that negative symptom data for brilaroxazine from the Phase 3 RECOVER trial & a long-term open-label extension trial will be presented at CNS Summit 2025.
  • The presentation covers data from patients with acute exacerbation of schizophrenia & those with clinically stable schizophrenia over a one-year period.
  • The poster presentation, titled "Brilaroxazine Treatment Effect on Negative Symptoms in Schizophrenia: RECOVER Trial in Acute and Stable Patients Over 1 Year," is assigned Poster Number 32.
  • The session is scheduled for November 3-4, 2025, from 5:00-7:00 PM ET in Boston, Massachusetts.
  • Reviva is a late-stage biopharmaceutical company focusing on CNS, inflammatory, & cardiometabolic diseases with a pipeline including brilaroxazine (RP5063) & RP1208.
  • Reviva holds composition of matter patents for both brilaroxazine & RP1208 in the United States, Europe, & other countries.